Fujifilm Diosynth Biotechnologies, a leading CDMO in the field of biologics, vaccines, advanced therapies, and oncolytic viruses, has embarked on the initial phase of a massive expansion project at their facility in Hillerød, Denmark. By adding six mammalian cell bioreactors to the existing infrastructure, the facility’s total now amounts to 12 bioreactors, each with a capacity of 20,000 liters. This move is integral to Fujifilm’s larger strategy, which strives to cultivate a global ecosystem aimed at revolutionizing the production and delivery of advanced medical solutions.
The next phase of this expansion, which hinges on significant capital investment, promises to further boost the facility’s capabilities. With plans to introduce eight additional bioreactors and two downstream processing streams, Fujifilm aims to commence fill/finish production by mid-2025. The entire expansion is expected to be concluded by 2026, ultimately increasing the site’s size to approximately 51,500 square meters. This ambitious project is anticipated to create up to 2,200 new jobs, reflecting Fujifilm’s commitment to not only improving healthcare but also contributing to local economies.
Fujifilm’s dedication to evolving the landscape of biologics manufacturing is evident in their substantial investment of over $8 billion since 2011. This investment has been channeled into developing a robust global manufacturing network characterized by modular facilities that offer scalable production capabilities. Among the most notable of these facilities is the one in Holly Springs, North Carolina, which is slated to become operational in 2025. These developments underscore Fujifilm’s intent to establish a flexible and transformative production network that can swiftly adapt to the changing needs of the biotech industry.
Lars Petersen, President and CEO of Fujifilm Diosynth Biotechnologies, highlighted that the Hillerød facility is just the beginning of broader global expansion plans. Future developments are already in the pipeline for the United States, United Kingdom, and Japan, showcasing Fujifilm’s commitment to international investment in state-of-the-art facilities and workforce development. This vision places Fujifilm Diosynth Biotechnologies in a pivotal position to meet the evolving requirements of their partners and the patients they serve, promising a dynamic and innovative future for biologics manufacturing.
